Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Application of the amplification-free SERS-based CRISPR/Cas12a platform in the identification of SARS-CoV-2 from clinical samples

Fig. 2

S-CRISPR for SARS-CoV-2 detection. a Titration of SARS-CoV-2 N gene-positive and -negative plasmids as detected by the S-CRISPR. The fitting model: [Inhibitor] vs. response—Variable slope (four parameters). Equation: Y = 6548 + (− 111.1–6548)/(1 + (1.204/X)−0.9674), R2  =  0.9665. b S-CRISPR was assessed using IVT RNA products from SARS-CoV-2. The fitting model: [Inhibitor] vs. response–Variable slope (four parameters). Equation: Y = 7074 + (724.2–7074)/(1 + (1.304/X)−1.201), R2  =  0.9937. c Initial validation of the storage life of the S-CRISPR assay. The components of the S-CRISPR assay were stored in 4 °C and 37 °C for up to 7 days, and the IVT RNA products (0.1 fM, 10 fM) were used to assess the signal change during the indicated storage period. The LoD was defined by a significant variation of Δ Raman signal at the lowest concentration. Standard deviations were determined based on three independent experiments

Back to article page